Humanized anti‐CD19 chimeric antigen receptor‐T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection

Chimeric antigen receptor‐T (CAR‐T) cell therapy is a promising treatment for CD19(+) B‐cell malignancies. However, elimination of B cells by anti‐CD19 CAR‐T cells may lead to the reactivation of hepatitis B virus (HBV) and related hepatitis in patients with HBV infection. This study aims to evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Rui, Lyu, Cuicui, Li, Qing, Jiang, Yanyu, Mou, Nan, Yang, Zhenxing, Liu, Xuxiang, Deng, Qi, Li, Lanfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983916/
https://www.ncbi.nlm.nih.gov/pubmed/32949412
http://dx.doi.org/10.1002/hon.2807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983916/
https://www.ncbi.nlm.nih.gov/pubmed/32949412
http://dx.doi.org/10.1002/hon.2807

Ejemplares similares